Acylcarnitines: Role in brain

Progress in Lipid Research

Volumn 49, Issue 1, 2010, Pages 61-75

  Jones, Lauren L ^a   McDonald, David A ^b   Borum, Peggy R ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Acetylcarnitine; Acylcarnitine; Brain metabolism; Carnitine; Ketogenic therapy

Indexed keywords

ACYLCARNITINE; ANTIOXIDANT; CARNITINE; FATTY ACID; NERVE GROWTH FACTOR; NEUROTRANSMITTER; PALMITOYLCARNITINE;

ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; APOPTOSIS; BRAIN METABOLISM; CHOLINERGIC TRANSMISSION; DRUG ACTIVITY; DRUG MECHANISM; DRUG STRUCTURE; ENERGY METABOLISM; EXCITOTOXICITY; FATTY ACID OXIDATION; GENE EXPRESSION; HUMAN; INBORN ERROR OF METABOLISM; INTRACTABLE EPILEPSY; KETOGENIC DIET; LIPOGENESIS; MAMMAL CELL; MITOCHONDRION; NERVE REGENERATION; NEUROLOGIC DISEASE; NEUROMODULATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW;

ACETYLCARNITINE; ANIMALS; ANTIOXIDANTS; BRAIN; CARNITINE; ENERGY METABOLISM; FATTY ACIDS; NERVE GROWTH FACTOR; NERVOUS SYSTEM DISEASES; NEUROPROTECTIVE AGENTS;

MAMMALIA;

EID: 71749085455     PISSN: 01637827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.plipres.2009.08.004     Document Type: Review

References (188)

1. Bieber L.L. Carnitine. Annu Rev Biochem 57 (1988) 261-283
2. Borum P.R. Carnitine. Annu Rev Nutr 3 (1983) 233-259
3. Ramsay R.R., and Zammit V.A. Carnitine acyltransferases and their influence on CoA pools in health and disease. Mol Aspects Med 25 (2004) 475-493
4. Foster D.W. The role of the carnitine system in human metabolism. Ann NY Acad Sci 1033 (2004) 1-16
5. Wu D.H., Govindasamy L., Lian W., et al. Structure of human carnitine acetyltransferase - molecular basis for fatty acyl transfer. J Biol Chem 278 (2003) 13159-13165
6. Hsiao Y.S., Jogl G., and Tong L. Structural and biochemical studies of the substrate selectivity of carnitine acetyltransferase. J Biol Chem 279 (2004) 31584-31589
7. Spiekerkoetter U., Tokunaga C., Wendel U., et al. Changes in blood carnitine and acylcarnitine profiles of very long-chain acyl-CoA dehydrogenase-deficient mice subjected to stress. Eur J Clin Invest 34 (2004) 191-196
8. Meyburg J., Schulze A., Kohlmueller D., et al. Acylcarnitine profiles of preterm infants over the first four weeks of life. Pediatr Res 52 (2002) 720-723
9. Wood J.C., Magera M.J., Rinaldo P., Seashore M.R., Strauss A.W., and Friedman A. Diagnosis of very long chain acyl-dehydrogenase deficiency from an infant's newborn screening card. Pediatrics 108 (2001) E19
10. Wikoff W.R., Gangoiti J.A., Barshop B.A., and Siuzdak G. Metabolomics identifies perturbations in human disorders of propionate metabolism. Clin Chem 53 (2007) 2169-2176
11. Clague A., and Thomas A. Neonatal biochemical screening for disease. Clin Chim Acta 315 (2002) 99-110
12. Meyburg J., Schulze A., Kohlmueller D., Linderkamp O., and Mayatepek E. Postnatal changes in neonatal acylcarnitine profile. Pediatr Res 49 (2001) 125-129
13. Chace D.H., Kalas T.A., and Naylor E.W. The application of tandem mass spectrometry to neonatal screening for inherited disorders of intermediary metabolism. Annu Rev Genom Hum Genet 3 (2002) 17-45
14. Koeberl D.D., Young S.P., Gregersen N., et al. Rare disorders of metabolism with elevated butyryl- and isobutyryl-carnitine detected by tandem mass spectrometry newborn screening. Pediatr Res 54 (2003) 219-223
15. Cavedon C.T., Bourdoux P., Mertens K., et al. Age-related variations in acylcarnitine and free carnitine concentrations measured by tandem mass spectrometry. Clin Chem 51 (2005) 745-752
16. Rinaldo P., Cowan T.M., and Matern D. Acylcarnitine profile analysis. Genet Med 10 (2008) 151-156
17. Roediger W.E., Heyworth M., Willoughby P., Piris J., Moore A., and Truelove S.C. Luminal ions and short chain fatty acids as markers of functional activity of the mucosa in ulcerative colitis. J Clin Pathol 35 (1982) 323-326
18. Bene J., Komlosi K., Gasztonyi B., Juhasz M., Tulassay Z., and Melegh B. Plasma carnitine ester profile in adult celiac disease patients maintained on long-term gluten free diet. World J Gastroenterol 11 (2005)
19. Bene J., Komlosi K., Havasi V., et al. Changes of plasma fasting carnitine ester profile in patients with ulcerative colitis. World J Gastroenterol 12 (2006) 110-113
20. Adams S.H., Hoppel C.L., Lok K.H., et al. Plasma acylcarnitine profiles suggest incomplete long-chain fatty acid beta-oxidation and altered tricarboxylic acid cycle activity in type 2 diabetic African-American women. J Nutr 139 (2009) 1073-1081
21. Pasquali M., Monsen G., Richardson L., Alston M., and Longo N. Biochemical findings in common inborn errors of metabolism. Am J Med Genet C Semin Med Genet 142C (2006) 64-76
22. Orlandi A., Francesconi A., Ferlosio A., et al. Propionyl-l-carnitine prevents age-related myocardial remodeling in the rabbit. J Cardiovasc Pharmacol 50 (2007) 168-175
23. Nalecz K.A., Szczepankowska D., Czeredys M., Kulikova N., and Grzeskiewicz S. Palmitoylcarnitine regulates estrification of lipids and promotes palmitoylation of GAP-43. FEBS Lett 581 (2007) 3950-3954
24. Pearson D.J., and Tubbs P.K. Carnitine and derivatives in rat tissues. Biochem J 105 (1967) 953-963
25. Frohlich J., Seccombe D.W., Hahn P., Dodek P., and Hynie I. Effect of fasting on free and esterified carnitine levels in human serum and urine: correlation with serum levels of free fatty acids and B-hydroxybutyrate. Metabolism 27 (1978) 555-561
26. Genuth S.M., and Hoppel C.L. Plasma and urine carnitine in diabetic ketosis. Diabetes 28 (1979) 1083-1087
27. Hoppel C.L., and Genuth S.M. Carnitine metabolism in normal-weight and obese human subjects during fasting. Am J Physiol 238 (1980) E409-E415
28. Murakami R., Tanaka A., and Nakamura H. The effect of starvation on brain carnitine concentration in neonatal rats. J Pediatr Gastroenterol Nutr 25 (1997) 385-387
29. Costa C.C.G., de Almeida I.T., Jakobs C., Poll-The B.T., and Duran M. Dynamic changes of plasma acylcarnitine levels induced by fasting and sunflower oil challenge test in children. Pediatr Res 46 (1999) 440-444
30. Kimura S., and Amemiya F. Brain and liver pathology in a patient with carnitine deficiency. Brain Dev 12 (1990) 436-439
31. Ebert D., Haller R.G., and Walton M.E. Energy contribution of octanoate to intact rat brain metabolism measured by C-13 nuclear magnetic resonance spectroscopy. J Neurosci 23 (2003) 5928-5935
32. Nalecz K.A., and Nalecz M.J. Carnitine - a known compound, a novel function in neural cells. Acta Neurobiol Exp [Warsz] 56 (1996) 597-609
33. Bresolin N., Freddo L., Vergani L., and Angelini C. Carnitine, carnitine acyltransferases, and rat brain function. Exp Neurol 78 (1982) 285-292
34. Rebouche C.J., and Engel A.J. Tissue distribution of carnitine biosynthetic enzymes in man. Biochim Biophys Acta 630 (1980) 22-29
35. Bird M.I., Munday L.A., Saggerson E.D., and Clark J.B. Carnitine acyltransferase activities in rat brain mitochondria. Biochem J 226 (1985) 323-330
36. Kido Y., Tamai I., Ohnari A., et al. Functional relevance of carnitine transporter OCTN2 to brain distribution of l-carnitine and acetyl-l-carnitine across the blood-brain barrier. J Neurochem 79 (2001) 959-969
37. --coupled active transport of carnitine by the amino acid transporter ATB[0, +] from mouse colon expressed in HRPE cells and Xenopus oocytes. J Physiol-London 532 (2001) 297-304
38. Sloan J.L., and Mager S. Cloning and functional expression of a human Na[+] and Cl[-]-dependent neutral and cationic amino acid transporter B[0, +]. J Biol Chem 274 (1999) 23740-23745
39. Nalecz K.A., Miecz D., Berezowski V., and Cecchelli R. Carnitine: transport and physiological functions in the brain. Mol Aspects Med 25 (2004) 551-567
40. Miecz D., Januszewicz E., Czeredys M., et al. Localization of organic cation/carnitine transporter [OCTN2] in cells forming the blood-brain barrier. J Neurochem 104 (2008) 113-123
41. Wawrzenczyk A., Nalecz K.A., and Nalecz M.J. Effect of externally added carnitine on the synthesis of acetylcholine in rat cerebral cortex cells. Neurochem Int 26 (1995) 635-641
42. Falchetto S., Kato G., and Provini L. The action of carnitines on cortical neurons. Can J Physiol Pharmacol 49 (1971) 1-7
43. Lamhonwah A.M., Hawkins C.E., Tam C., Wong J., Mai L., and Tein I. Expression patterns of the organic cation/carnitine transporter family in adult murine brain. Brain Dev 30 (2008) 31-42
44. Forloni G., Angeretti N., and Smiroldo S. Neuroprotective activity of acetyl-l-carnitine: Studies in vitro. J Neurosci Res 37 (1994) 92-96
45. Spagnoli A., Lucca U., Menasce G., et al. Long-term acetyl-l-carnitine treatment in Alzheimer's disease. Neurology 41 (1991) 1726-1732
46. Adams R.J., Cohen D.W., Gupte S., et al. In vitro effects of palmitylcarnitine on cardiac plasma membrane Na, K-ATPase, and sarcoplasmic reticulum Ca2+ ATPase and Ca2+ transport. J Biol Chem 254 (1979) 12404-12410
47. Haruna T., Horie M., Takano M., et al. Alteration of the membrane lipid environment by l-palmitoylcarnitine modulates K[ATP] channels in guinea-pig ventricular myocytes. Pflugers Arch 441 (2000) 200-207
48. Liu Q.Y., and Rosenberg R.L. Activation and inhibition of reconstituted cardiac l-type calcium channels by palmitoyl-l-carnitine. Biochem Biophys Res Commun 228 (1996) 252-258
49. Shen J.B., and Pappano A.J. Palmitoyl-l-carnitine acts like ouabain on voltage, current, and contraction in guinea pig ventricular cells. Am J Physiol Heart Circ Physiol 268 (1995) H1027-H1036
50. Arduini A., Mancinelli G., Radatti G.L., Dottori S., Molajoni F., and Ramsay R.R. Role of carnitine and carnitine palmitoyltransferase as integral components of the pathway for membrane phospholipid fatty acid turnover in intact human erythrocytes. J Biol Chem 267 (1992) 12673-12681
51. Arduini A., Denisova N., Virmani A., Avrova N., Federici G., and Arrigoni-Martelli E. Evidence for the involvement of carnitine-dependent long-chain acyltransferases in neuronal triglyceride and phospholipid fatty acid turnover. J Neurochem 62 (1994) 1530-1538
52. Szczepankowska D., and Nalecz K.A. Palmitoylcarnitine modulates palmitoylatjion of proteins: implication for differentiation of neural cells. Neurochem Res 28 (2003) 645-651
53. Price N.T., van der Leij F.R., Jackson V.N., et al. A novel brain-expressed protein related to carnitine palmitoyltransferase I. Genomics 80 (2002) 433-442
54. Wolfgang M.J., Cha S.H., Millington D.S., et al. Brain-specific carnitine palmitoyl-transferase-1c: role in CNS fatty acid metabolism, food intake, and body weight. J Neurochem 105 (2008) 1550-1559
55. Sierra A.Y., Gratacos E., Carrasco P., et al. CPT1c is localized in endoplasmic reticulum of neurons and has carnitine palmitoyltransferase activity. J Biol Chem 283 (2008) 6878-6885
56. Mutomba M.C., Yuan H., Konyavko M., et al. Regulation of the activity of caspases by l-carnitine and palmitoylcarnitine. FEBS Lett 478 (2000) 19-25
57. Muraki K., and Imaizumi Y. A novel action of palmitoyl-l-carnitine in human vascular endothelial cells. J Pharmacol Sci 92 (2003) 252-258
58. Nalecz K.A., Mroczkowska J.E., Berent U., and Nalecz M.J. Effect of palmitoylcarnitine on the cellular differentiation, proliferation and protein kinase C activity in neuroblastoma nb-2a cells. Acta Neurobiol Exp [Warsz] 57 (1997) 263-274
59. Sobiesiak-Mirska J., Nalecz M.J., and Nalecz K.A. Interaction of palmitoylcarnitine with protein kinase C in neuroblastoma NB-2a cells. Neurochem Int 42 (2003) 45-55
60. Mizgalska J.A., Berent U., Mac M., et al. Accumulation of palmitoylcarnitine in neuroblastoma NB-2a cells affects the expression, phosphorylation and localization of B-50 protein. Neurosci Res Commun 22 (1998) 73-82
61. Shug A.L., Schmidt M.J., Golden G.T., and Fariello R.G. The distribution and role of carnitine in the mammalian brain. Life Sci 31 (1982) 2869-2874
62. Parnetti L., Gaiti A., Mecocci P., Cadini D., and Senin U. Pharmacokinetics of IV and oral acetyl-l-carnitine in a multiple dose regimen in patients with senile dementia of Alzheimer type. Eur J Clin Pharmacol 42 (1992) 89-93
63. Aureli T., Di Cocco M.E., Pucetti C., et al. Acetyl-l-carnitine modulates glucose metabolism and stimulates glycogen synthesis in rat brain. Brain Res 796 (1998) 75-81
64. Gorini A., D'Angelo A., and Villa R.F. Action of l-acetylcarnitine on different cerebral mitochondrial populations from cerebral cortex. Neurochem Res 23 (1998) 1485-1491
65. Calabrese V., Stella A.M.G., Calvani M., and Butterfield D.A. Acetylcarnitine and cellular stress response: roles in nutritional redox homeostasis and regulation of longevity genes. J Nutr Biochem 17 (2006) 73-88
66. Zanelli S.A., Solenski N.J., Rosenthal R.E., and Fiskum G. Mechanisms of ischemic neuroprotection by acetyl-l-carnitine (2005), New York Acad Sciences, New York
67. Virmani A., and Binienda Z. Role of carnitine esters in brain neuropathology. Mol Aspects Med 25 (2004) 533-549
68. Pettegrew J.W., Levine J., and McClure R.J. Acetyl-l-carnitine physical-chemical, metabolic, and therapeutic properties: relevance for its mode of action in Alzheimer's disease and geriatric depression. Mol Psychiatry 5 (2000) 616-632
69. Farrell S., Vogel J., and Bieber L.L. Entry of acetyl-l-carnitine into biosynthetic pathways. Biochim Biophys Acta 876 (1986) 175-177
70. Ricciolini R., Scalibastri M., Kelleher J.K., Carminati P., Calvani M., and Arduini A. Role of acetyl-l-carnitine in rat brain lipogenesis: Implications for polyunsaturated fatty acid biosynthesis. J Neurochem 71 (1998) 2510-2517
71. Pettegrew J.W., Klunk W.E., Panchalingam K., Kanfer J.N., and McClure R.J. Clinical and neurochemical effects of acetyl-l-carnitine in Alzheimer's disease. Neurobiol Aging 16 (1995) 1-4
72. Aureli T., Miccheli A., and Ricciolini R. Et al. Aging brain: effect of acetyl-l-carnitine treatment on rat brain energy and phospholipid metabolism. A study by 31P and 1H NMR spectroscopy. Brain Res 526 (1990) 108-112
73. Aureli T., Miccheli A., Di Cocco M.E., et al. Effect of acetyl-l-carnitine on recovery of brain phosphorus metabolites and lactic acid level during reperfusion after cerebral ischemia in the rat-Study by 13P- and 1H-NMR spectroscopy. Brain Res 643 (1994) 92-99
74. Rosenthal R.E., Williams R., Bogaert Y.E., Getson P.R., and Fiskum G. Prevention of postischemic canine neurological injury through potentiation of brain energy metabolism by acetyl-l-carnitine. Stroke 23 (1992) 1312-1318
75. Conley K.E., Marcinek D.J., and Villarin J. Mitochondrial dysfunction and age. Curr Opin Clin Nutr Metab Care 10 (2007) 688-692
76. Hagen T.M., Ingersoll R.T., Wehr C.M., et al. Acetyl-l-carnitine fed to old rats partially restores mitochondrial function and ambulatory activity. Proc Natl Acad Sci USA 95 (1998) 9562-9566
77. Ames B.N., and Liu J. Delaying the mitochondrial decay of aging with acetylcarnitine. Ann NY Acad Sci 1033 (2004) 108-116
78. Aureli T., Di Cocco M.E., Capuani G., et al. Effect of long-term feeding with acetyl-l-carnitine on the age-related changes in rat brain lipid composition: a study by P-31 NMR spectroscopy. Neurochem Res 25 (2000) 395-399
79. Hagen T.M., Liu J.K., Lykkesfeldt J., et al. Feeding acetyl-l-carnitine and lipoic acid to old rats significantly improves metabolic function while decreasing oxidative stress. Proc Natl Acad Sci USA 99 (2002) 1870-1875
80. Long J.G., Gao F., Tong L.Q., Cotman C.W., Ames B.N., and Liu J.K. Mitochondrial decay in the brains of old rats: ameliorating effect of alpha-lipoic acid and acetyl-l-carnitine. Neurochem Res 34 (2009) 755-763
81. Aliev G., Liu J., Shenk J.C., et al. Neuronal mitochondrial amelioration by feeding acetyl-l-carnitine and lipoic acid to aged rats. J Cell Mol Med 13 (2009) 320-333
82. Cassano P., Sciancalepore A.G., Pesce V., et al. Acetyl-l-carnitine feeding to unloaded rats triggers in soleus muscle the coordinated expression of genes involved in mitochondrial biogenesis. Biochim Biophys Acta-Bioenerg 1757 (2006) 1421-1428
83. Blokland A., Bothmer J., Honig W., and Jolles J. Behavioural and biochemical effects of acute central metabolic inhibition: effects of acetyl-l-carnitine. Eur J Pharmacol 235 (1993) 275-281
84. Virmani M.A., Biselli R., Spadoni A., et al. Protective actions of l-carnitine and acetyl-l-carnitine on the neurotoxicity evoked by mitochondrial uncoupling or inhibitors. Pharmacol Res 32 (1995) 383-389
85. Virmani M.A., Caso V., Spadoni A., Rossi S., Russo F., and Gaetani F. The action of acetyl-l-carnitine on the neurotoxicity evoked by amyloid fragments and peroxide on primary rat cortical neurones. Neuroprotect Agents 939 (2001) 162-178
86. Farooqui A.A., Horrocks L.A., and Farooqui T. Modulation of inflammation in brain: a matter of fat. J Neurochem 101 (2007) 577-599
87. Murphy E.J., Schapiro M.B., Rapoport S.I., and Shetty H.U. Phospholipid composition and levels are altered in down syndrome brain. Brain Res 867 (2000) 9-18
88. Farooqui A.A., Rapoport S.I., and Horrocks L.A. Membrane phospholipid alterations in Alzheimer's disease: deficiency of ethanolamine plasmalogens. Neurochem Res 22 (1997) 523-527
89. Söderberg M., Edlund C., Kristensson K., and Dallner G. Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease. Lipids 26 (1991) 421-425
90. Puri B.K. Impaired phospholipid-related signal transduction in advanced Huntington's disease. Exp Physiol 86 (2001) 683-685
91. Infante J.P., and Huszagh V.A. On the molecular etiology of decreased arachidonic [20:4n-6], docosapentaenoic [22:5n-6] and docosahexaenoic [22:6n-3] acids in Zellweger syndrome and other peroxisomal disorders. Mol Cell Biochem 168 (1997) 101-115
92. Infante J.P. A function for the vitamin E metabolite alpha-tocopherol quinone as an essential enzyme cofactor for the mitochondrial fatty acid desaturases. FEBS Lett 446 (1999) 1-5
93. Infante J.P., and Huszagh V.A. Secondary carnitine deficiency and impaired docosahexaenoic [22:6n-3] acid synthesis: a common denominator in the pathophysiology of diseases of oxidative phosphorylation and beta-oxidation. FEBS Lett 468 (2000) 1-5
94. Horrocks L.A., and Farooqui A.A. Docosahexaenoic acid in the diet: its importance in maintenance and restoration of neural membrane function. Prostag Leukotr Essent Fatty Acids 70 (2004) 361-372
95. Hinerfeld D., Traini M.D., Weinberger R.P., et al. Endogenous mitochondrial oxidative stress: neurodegeneration, proteomic analysis, specific respiratory chain defects, and efficacious antioxidant therapy in superoxide dismutase 2 null mice. J Neurochem 88 (2004) 657-667
96. Bagetta V., Barone I., Ghiglieri V., et al. Acetyl-l-Carnitine selectively prevents post-ischemic LTP via a possible action on mitochondrial energy metabolism. Neuropharmacology 55 (2008) 223-229
97. Alves E., Binienda Z., Carvalho F., et al. Acetyl-l-carnitine provides effective in vivo neuroprotection over 3,4-methylenedioximethamphetamine-induced mitochondrial neurotoxicity in the adolescent rat brain. Neuroscience 158 (2009) 514-523
98. Virmani A, Gaetani F, Binienda Z, Xu A, Duhart H, Ali SF. Role of mitochondrial dysfunction in neurotoxicity of MPP+ - Partial protection of PC12 cells by acetyl-l-carnitine. Current Status of Drug Dependence/Abuse Studies: Cellular and Molecular Mechanisms of Drugs of Abuse and Neurotoxicity 2004;1025:267-73.
99. Bodis-Wollner I., Chung E., Ghilardi M.F., et al. Acetyl-levo-carnitine protects against MPTP-induced parkinsonism in primates. J Neural Transm Park Dis Dement Sect 3 (1991) 63-72
100. Mazzio E., Yoon K.J., and Soliman K.F.A. Acetyl-l-carnitine cytoprotection against 1-methyl-4-phenylpyridinium toxicity in neuroblastoma cells. Biochem Pharmacol 66 (2003) 297-306
101. Binienda Z., Johnson J.R., Tyler-Hashemi A.A., et al. Protective effect of l-carnitine in the neurotoxicity induced by the mitochondrial inhibitor 3-nitropropionic acid [3-NPA]. Neuroprotect Agents: Fourth Int Conf 890 (1999) 173-178
102. Binienda Z.K. Neuroprotective effects of l-carnitine in induced mitochondrial dysfunction. Neuroprotect Agents 993 (2003) 289-295
103. Silva-Adaya D., Perez-De La Cruz V., Herrera-Mundo M.N., et al. Excitotoxic damage, disrupted energy metabolism, and oxidative stress in the rat brain: antioxidant and neuroprotective effects of l-carnitine. J Neurochem 105 (2008) 677-689
104. Schapira A.H.V. Mitochondrial involvement in Parkinson's disease, Huntington's disease, hereditary spastic paraplegia and Friedreich's ataxia. Biochim Biophys Acta-Bioenerg 1410 (1999) 159-170
105. Binienda Z., Virmani A., Przybyla-Zawislak B., and Schmued L. Neuroprotective effect of l-carnitine in the 3-nitropropionic acid [3-NPA]-evoked neurotoxicity in rats. Neurosci Lett 367 (2004) 264-267
106. Hino K., Nishikawa M., Sato E., and Inoue M. l-carnitine inhibits hypoglycemia-induced brain damage in the rat. Brain Res 1053 (2005) 77-87
107. Wallace D.C. Mitochondrial diseases in man and mouse. Science 283 (1999) 1482-1488
108. DiMauro S., and Schon E.A. Nuclear power and mitochondrial disease. Nat Genet 19 (1998) 214-215
109. Sue C.M., Hirano M., DiMauro S., and De Vivo D.C. Neonatal presentations of mitochondrial metabolic disorders. Semin Perinatol 23 (1999) 113-124
110. Buttriss J.L., and Diplock A.T. The relationship between alpha-tocopherol and phospholipid fatty acids in rat liver subcellular membrane fractions. Biochim Biophys Acta 962 (1988) 81-90
111. Raederstorff D., Meier C.A., Moser U., and Walter P. Hypothyroidism and thyroxin substitution affect the n-3 fatty acid composition of rat liver mitochondria. Lipids 26 (1991) 781-787
112. Calabrese V., Ravagna A., Colombrita C., et al. Acetylcarnitine induces heme oxygenase in rat astrocytes and protects against oxidative stress: Involvement of the transcription factor Nrf2. J Neurosci Res 79 (2005) 509-521
113. Calabrese V., Colombrita C., Sultana R., et al. Redox modulation of heat shock protein expression by acetylcarnitine in aging brain: relationship to antioxidant status and mitochondrial function. Antioxid Redox Signal 8 (2006) 404-416
114. Poon H.F., Calabrese V., Calvani M., and Butterfield D.A. Proteomics analyses of specific protein oxidation and protein expression in aged rat brain and its modulation by l-acetylcarnitine: insights into the mechanisms of action of this proposed therapeutic agent for CNS disorders associated with oxidative stress. Antioxid Redox Signal 8 (2006) 381-394
115. Abdul H.M., Calabrese V., Calvani M., and Butterfield D.A. Acetyl-l-carnitine-induced up-regulation of heat shock proteins protects cortical neurons against amyloid-beta peptide 1-42-mediated oxidative stress and neurotoxicity: implications for Alzheimer's disease. J Neurosci Res 84 (2006) 398-408
116. Abdul H.M., and Butterfield D.A. Involvement of PI3K/PKG/ERK1/2 signaling pathways in cortical neurons to trigger protection by cotreatment of acetyl-l-carnitine and alpha-lipoic acid against HNE-mediated oxidative stress and neurotoxicity: Implications for Alzheimer's disease. Free Radic Biol Med 42 (2007) 371-384
117. Lowitt S., Malone J.I., Salem A.F., Korthals J., and Benford S. Acetyl-l-carnitine corrects the altered peripheral nerve function of experimental diabetes. Metabolism 44 (1995) 677-680
118. Liu J., Head E., Kuratsune H., Cotman C.W., and Ames B.N. Comparison of the effects of l-carnitine and acetyl-l-carnitine on carnitine levels, ambulatory activity, and oxidative stress biomarkers in the brain of old rats. Ann NY Acad Sci 1033 (2004) 117-131
119. Winter B.K., Fiskum G., and Gallo L.L. Effects of l-carnitine on serum triglyceride and cytokine levels in rat models of cachexia and septic shock. Br J Cancer 72 (1995) 1173-1179
120. Furuno T., Kanno T., Arita K., et al. Roles of long chain fatty acids and carnitine in mitochondrial membrane permeability transition. Biochem Pharmacol 62 (2001) 1037-1046
121. Pillich R.T., Scarsella G., and Risuleo G. Reduction of apoptosis through the mitochondrial pathway by the administration of acetyl-l-carnitine to mouse fibroblasts in culture. Exp Cell Res 306 (2005) 1-8
122. Ishii T., Shimpo Y., Kinoshita K., and Kinoshita K. Anti-apoptotic effect of acetyl-l-carnitine and l-carnitine in primary cultured neurons. Jpn J Pharmacol 83 (2000) 119-124
123. Zhu X.P., Sato E.F., Wang Y., Nakamura H., Yodoi J., and Inoue M. Acetyl-l-carnitine suppresses apoptosis of thioredoxin 2-deficient DT40 cells. Arch Biochem Biophys 478 (2008) 154-160
124. Furlong J.H. Acetyl-l-carnitine: metabolism and applications in clinical practice. Altern Med Rev 1 (1996) 85-93
125. Foreman P.J., Perez-Polo J.R., Angelucci L., Ramacci M.T., and Taglialatela G. Effects of acetyl-l-carnitine treatment and stress exposure on the nerve growth factor receptor [p75NGFR] mRNA level in the central nervous system of aged rats. Prog Neuropsychopharmacol Biol Psychiat 19 (1995) 117-133
126. Sima A.A.F., Ristic H., Merry A., et al. Primary preventive and secondary interventionary effects of acetyl-l-carnitine on diabetic neuropathy in the bio-breeding Worcester rat. J Clin Invest 97 (1996) 1900-1907
127. De Angelis C., Scarfò C., Falcinelli M., et al. Acetyl-l-carnitine prevents age-dependent structural alterations in rat peripheral nerves and promotes regeneration following sciatic nerve injury in young and senescent rats. Exp Neurol 128 (1994) 103-114
128. Bigini P., Larini S., Pasquali C., Muzio V., and Mennini T. Acetyl-l-carnitine shows neuroprotective and neurotrophic activity in primary culture of rat embryo motoneurons. Neurosci Lett 329 (2002) 334-338
129. Evans J.D., Jacobs T.F., and Evans E.W. Role of acetyl-l-carnitine in the treatment of diabetic peripheral neuropathy. Ann Pharmacother 42 (2008) 1686-1691
130. Lombardo P., Scuri R., Cataldo E., et al. Acetyl-l-carnitine induces a sustained potentiation of the after hyperpolarization. Neuroscience 128 (2004) 293-303
131. Kuratsune H., Yamaguti K., Lindh G., et al. Brain regions involved in fatigue sensation: reduced acetylcarnitine uptake into the brain. Neuroimage 17 (2002) 1256-1265
132. Malaguarnera M., Gargante M.P., Cristaldi E., et al. Acetyl-l-carnitine [ALC] treatment in elderly patients with fatigue. Arch Gerontol Geriatr 46 (2008) 181-190
133. White H.L., and Scates P.W. Acetyl-l-carnitine as a precursor of acetylcholine. Neurochem Res 15 (1990) 597-601
134. Ando S., Tadenuma T., Tanaka Y., et al. Enhancement of learning capacity and cholinergic synaptic function by carnitine in aging rats. J Neurosci Res 66 (2001) 266-271
135. Imperato A., Ramacci M.T., and Angelucci L. Acetyl-l-carnitine enhances acetylcholine release in the striatum and hippocampus of awake freely moving rats. Neurosci Lett 107 (1989) 251-255
136. Picconi B., Barone I., Pisani A., et al. Acetyl-l-carnitine protects striatal neurons against in vitro ischemia: the role of endogenous acetylcholine. Neuropharmacology 50 (2006) 917-923
137. Calvani M., Carta A., Caruso G., Benedetti N., and Iannuccelli M. Action of acetyl-l-carnitine in neurodegeneration and Alzheimer's disease. Ann NY Acad Sci 663 (1992) 483-486
138. Szutowicz A., Bielarczyk H., Gul S., Zielinski P., Pawelczyk T., and Tomaszewicz M. Nerve growth factor and acetyl-l-carnitine evoked shifts in acetyl-CoA and cholinergic SN56 cell vulnerability to neurotoxic inputs. J Neurosci Res 79 (2005) 185-192
139. Calvani M., Lannuccelli M., Colasimone D., and Orfalian Z. Chronicle of the development of an endogenous substance for dementia: acetyl-l-carnitine. In: Bes A. (Ed). Senile dementias: early detection (1986), John Libbey Eurotext 394-400
140. Bonavita E. Study of the efficacy and tolerability of l-acetylcarnitine therapy in the senile brain. Int J Clin Pharmacol 24 (1986) 511-516
141. Sershen H., Harsing Jr. L.G., Banay-Schwartz M., Hashim A., Ramacci M.T., and Lajtha A. Effect of acetyl-l-carnitine on the dopaminergic system in aging brain. J Neurosci Res 30 (1991) 555-559
142. Fariello R.G., Ferraro T.N., Golden G.T., and DeMattei M. Systemic acetyl-l-carnitine elevates NigralLevels of glutathione and GABA. Life Sci 43 (1988) 289-292
143. Bahring R., Standhardt H., Martelli E.A., and Grantyn R. GABA-activated chloride currents of postnatal mouse retinal ganglion cells are blocked by acetylcholine and acetylcarnitine: how specific are ion channels in immature neurons?. Eur J Neurosci 6 (1994) 1089-1099
144. Tanaka M., Nakamura F., Mizokawa S., Matsumura A., Matsumura K., and Watanabe Y. Role of acetyl-l-carnitine in the brain: revealed by bioradiography. Biochem Biophys Res Commun 306 (2003) 1064-1069
145. Bhaumik S.R., Smith E., and Shilatifard A. Covalent modifications of histones during development and disease pathogenesis. Nat Struct Mol Biol 14 (2007) 1008-1016
146. Traina G., Valleggi S., Bernardi R., et al. Identification of differentially expressed genes induced in the rat brain by acetyl-l-carnitine as evidenced by suppression subtractive hybridisation. Mol Brain Res 132 (2004) 57-63
147. Traina G., Federighi G., Brunelli M., and Scuri R. Cytoprotective effect of acetyl-l-carnitine evidenced by analysis of gene expression in the rat brain. Mol Neurobiol 39 (2009) 101-106
148. Traina G., Bernardi R., Cataldo E., Macchi M., Durante M., and Brunelli M. In the rat brain acetyl-l-carnitine treatment modulates the expression of genes involved in neuronal ceroid lipofuscinosis. Mol Neurobiol 38 (2008) 146-152
149. Traina G., Federighi G., and Brunelli M. Up-regulation of kinesin light-chain 1 gene expression by acetyl-l-carnitine: therapeutic possibility in Alzheimer's disease. Neurochem Int 53 (2008) 244-247
150. Avruch J., Zhang X.F., and Kyriakis J.M. Raf meets Ras: completing the framework of a signal transduction pathway. Trends Biochem Sci 19 (1994) 279-283
151. Thorson J.A., Yu L.W., Hsu A.L., et al. 14-3-3 proteins are required for maintenance of Raf-1 phosphorylation and kinase activity. Mol Cell Biol 18 (1998) 5229-5238
152. Fountoulakis M., Cairns N., and Lubec G. Increased levels of 14-3-3 gamma and epsilon proteins in brain of patients with Alzheimer's disease and Down syndrome. J Neural Transm Suppl 57 (1999) 323-335
153. Mateo I., Llorca J., Infante J., Rodriguez-Rodriguez E., Berciano J., and Combarros O. Gene-gene interaction between 14-3-3 zeta and butyrylcholinesterase modulates Alzheimer's disease risk. Eur J Neurol 15 (2008) 219-222
154. Yan W.L., Lerner T.J., Haines J.L., and Gusella J.F. Sequence analysis and mapping of a novel human mitochondrial ATP synthase subunit 9 cDNA [ATP5G3]. Genomics 24 (1994) 375-377
155. Calabrese V., Scapagnini G., Ravagna A., et al. Increased expression of heat shock proteins in rat brain during aging: relationship with mitochondrial function and glutathione redox state. Mech Ageing Dev 125 (2004) 325-335
156. Traina G., Bernardi R., Rizzo M., Calvani M., Durante M., and Brunelli M. Acetyl-l-carnitine up-regulates expression of voltage-dependent anion channel in the rat brain. Neurochem Int 48 (2006) 673-678
157. Steiber A., Kerner J., and Hoppel C.L. Carnitine: a nutritional, biosynthetic, and functional perspective. Mol Aspects Med 25 (2004) 455-473
158. Chiechio S., Caricasole A., Barletta E., et al. l-acetylcarnitine induces analgesia by selectively up-regulating mGlu2 metabotropic glutamate receptors. Mol Pharmacol 61 (2002) 989-996
159. Chiechio S., Copani A., De Petris L., Morales M.E.P., Nicoletti F., and Gereau R.W. Transcriptional regulation of metabotropic glutamate receptor 2/3 expression by the NF-kappa B pathway in primary dorsal root ganglia neurons: a possible mechanism for the analgesic effect of l-acetylcarnitine. Molecular Pain 2 (2006)
160. Filipek P.A., Juranek J., Nguyen M.T., Cummings C., and Gargus J.J. Relative carnitine deficiency in autism. J Autism Dev Disord 34 (2004) 615-623
161. Beal M.F. Bioenergetic approaches for neuroprotection in Parkinson's disease. Ann Neurol 53 (2003) S39-S47
162. Pueschel S.M. The effect of acetyl-l-carnitine administration on persons with Down syndrome. Res Dev Disabil 27 (2006) 599-604
163. Wainwright M.S., Mannix M.K., Brown J., and Stumpf D.A. l-carnitine reduces brain injury after hypoxia-ischemia in newborn rats. Pediatr Res 54 (2003) 688-695
164. Goety C.G., Tanner C.M., Cohen J.A., et al. l-acetyl-carnitine in Huntington's disease: double-blind placebo controlled crossover study of drug effects on movement disorder and dementia. Mov Disord 5 (1990) 263-265
165. Sorbi S., Forleo P., Fani C., and Piacentini S. Double-blind, crossover, placebo-controlled clinical trial with l-acetylcarnitine in patients with degenerative cerebellar ataxia. Clin Neuropharmacol 23 (2000) 114-118
166. Salvioli G., and Neri M. l-acetylcarnitine treatment of mental decline in the elderly. Drugs Exp Clin Res 20 (1994) 169-176
167. Herrmann W.M., Dietrich B., and Hiersemenzel R. Pharmaco-electroencephalographic and clinical effects of the cholinergic substance - acetyl-l-carnitine - in patients with organic brain syndrome. Int J Clin Pharmacol Res 10 (1990) 81-84
168. Malaguarnera M., Gargante M.P., Cristaldi E., et al. Acetyl-l-carnitine treatment in minimal hepatic encephalopathy. Dig Dis Sci 53 (2008) 3018-3025
169. Matsuoka M., and Igisu H. Comparison of the effects of l-carnitine, d-carnitine and acetyl-l-carnitine on the neurotoxicity of ammonia. Biochem Pharmacol 46 (1993) 159-164
170. Malaguarnera M., Risino C., Cammalleri L., et al. Branched chain amino acids supplemented with l-acetylcarnitine versus BCAA treatment in hepatic coma: a randomized and controlled double blind study. Eur J Gastroenterol Hepatol 21 (2009) 762-770
171. Cao Y., Wang Y.X., Liu C.J., Wang L.X., Han Z.W., and Wang C.B. Comparison of pharmacokinetics of l-carnitine, acetyl-l-carnitine and propionyl-l-carnitine after single oral administration of l-carnitine in healthy volunteers. Clin Invest Med 32 (2009) E13-E19
172. Reuter S.E., Evans A.M., Chace D.H., and Fornasini G. Determination of the reference range of endogenous plasma carnitines in healthy adults. Ann Clin Biochem 45 (2008) 585-592
173. Keating D.J. Mitochondrial dysfunction, oxidative stress, regulation of exocytosis and their relevance to neurodegenerative diseases. J Neurochem 104 (2008) 298-305
174. PALAY S.L. Synapses in the central nervous system. J Biophys Biochem Cytol 2 (1956) 193-202
175. Dhitavat S., Ortiz D., Shea T.B., and Rivera E.R. Acetyl-l-carnitine protects against amyloid-beta neurotoxicity: roles of oxidative buffering and ATP levels. Neurochem Res 27 (2002) 501-505
176. Montgomery S.A., Thal L.J., and Amrein R. Meta-analysis of double blind randomized controlled clinical trials of acetyl-l-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease. Int Clin Psychopharmacol 18 (2003) 61-71
177. Thal L.J., Calvani M., Amato A., and Carta A. A 1-year controlled trial of acetyl-l-carnitine in early-onset AD. Neurology 55 (2000) 805-810
178. Simpson I.A., Carruthers A., and Vannucci S.J. Supply and demand in cerebral energy metabolism: the role of nutrient transporters. J Cereb Blood Flow Metab 27 (2007) 1766-1791
179. McGarry J.D., Robles-Valdes C., and Foster D.W. Role of carnitine in hepatic ketogenesis. Proc Natl Acad Sci USA 72 (1975) 4385-4388
180. Parvin R., and Pande S.V. Enhancement of mitochondrial carnitine and carnitine acylcarnitine translocase-mediated transport of fatty acids into liver mitochondria under ketogenic conditions. J Biol Chem 254 (1979) 5423-5429
181. Brass E.P., and Hoppel C.L. Relationship between acid-soluble carnitine and coenzyme a pools in vivo. Biochem J 190 (1980) 495-504
182. Hack A., Busch V., Pascher B., et al. Monitoring of ketogenic diet for carnitine metabolites by subcutaneous microdialysis. Pediatr Res 60 (2006) 93-96
183. Gravina E., and Gravina-Sanvitale G. Effect of carnitine on blood acetoacetate in fasting children. Clin Chim Acta 23 (1969) 376-377
184. Kuratsune H., Watanabe Y., Yamaguti K., et al. High uptake of [2-[11]]acetyl-l-carnitine into the brain: a pet study. Biochem Biophys Res Commun 231 (1997) 488-493
185. Bough K.J., Wetherington J., Hassel B., et al. Mitochondrial biogenesis in the anticonvulsant mechanism of the ketogenic diet. Ann Neurol 60 (2006) 223-235
186. Liu JK, Atamna H, Kuratsune H, Ames BN. Delaying brain mitochondrial decay and aging with mitochondrial antioxidants and metabolites. Increasing Healthy Life Span: Conventional Measures and Slowing the Innate Aging Process 2002;959:133-66.
187. Ma W., Berg J., and Yellen G. Ketogenic diet metabolites reduce firing in central neurons by opening K[ATP] channels. J Neurosci 27 (2007) 3618-3625
188. Li S.Y., Liu Y., Sigmon V.K., McCort A., and Ren J. High-fat diet enhances visceral advanced glycation end products, nuclear O-Glc-Nac modification, p38 mitogen-activated protein kinase activation and apoptosis. Diabetes Obes Metab 7 (2005) 448-454